IL127142A0 - Immune cells having predefined biological specificity - Google Patents
Immune cells having predefined biological specificityInfo
- Publication number
- IL127142A0 IL127142A0 IL12714298A IL12714298A IL127142A0 IL 127142 A0 IL127142 A0 IL 127142A0 IL 12714298 A IL12714298 A IL 12714298A IL 12714298 A IL12714298 A IL 12714298A IL 127142 A0 IL127142 A0 IL 127142A0
- Authority
- IL
- Israel
- Prior art keywords
- immune cells
- biological specificity
- predefined biological
- predefined
- specificity
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12714298A IL127142A0 (en) | 1998-11-19 | 1998-11-19 | Immune cells having predefined biological specificity |
PCT/IL1999/000622 WO2000031239A1 (en) | 1998-11-19 | 1999-11-18 | Immune cells having predefined biological specificity, comprising chimeric t cell receptor |
AU12927/00A AU1292700A (en) | 1998-11-19 | 1999-11-18 | Immune cells having predefined biological specificity, comprising chimeric t cell receptor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12714298A IL127142A0 (en) | 1998-11-19 | 1998-11-19 | Immune cells having predefined biological specificity |
Publications (1)
Publication Number | Publication Date |
---|---|
IL127142A0 true IL127142A0 (en) | 1999-09-22 |
Family
ID=11072157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12714298A IL127142A0 (en) | 1998-11-19 | 1998-11-19 | Immune cells having predefined biological specificity |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1292700A (en) |
IL (1) | IL127142A0 (en) |
WO (1) | WO2000031239A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100388942B1 (en) * | 2000-07-08 | 2003-06-25 | 한화석유화학 주식회사 | A Single Chain Variable Fragment of an Antibody for Protein Expressed on Cell Surface of Human Cortical Thymocyte and Leukemic Cell |
US20030012782A1 (en) * | 2000-08-11 | 2003-01-16 | Gold Daniel P. | Method and composition for altering a T cell mediated pathology |
ATE338124T1 (en) * | 2000-11-07 | 2006-09-15 | Hope City | CD19-SPECIFIC TARGETED IMMUNE CELLS |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
DE10259713A1 (en) * | 2002-12-19 | 2004-07-08 | Johannes-Gutenberg-Universität Mainz | Process for the stabilization of expression and improvement of the specific effector function of single chain antigen-recognizing genetic constructs (scARC) and corresponding mutated MDM2 protein specific scT cell receptors |
WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
WO2007073147A1 (en) * | 2005-12-20 | 2007-06-28 | Erasmus University Medical Center Rotterdam | Apoptosis-inducing protein complexes and therapeutic use thereof |
ES2595307T3 (en) | 2007-01-31 | 2016-12-29 | Yeda Research And Development Company Limited | Redirected, genetically modified regulatory T cells and their use in the suppression of autoimmune and inflammatory diseases |
WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
EP2566954B2 (en) | 2010-05-04 | 2022-11-02 | Yeda Research and Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
EP2755997B1 (en) * | 2011-09-15 | 2018-07-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
EP2760892A1 (en) * | 2011-09-29 | 2014-08-06 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
EP3470434A1 (en) | 2012-01-13 | 2019-04-17 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
GB201501175D0 (en) | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
EP3285877B1 (en) | 2015-04-21 | 2022-10-19 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
US11241455B2 (en) | 2016-01-15 | 2022-02-08 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of treating disease by metabolic control of T-cell differentiation |
CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
JP2020503883A (en) | 2017-01-13 | 2020-02-06 | アジェナス インコーポレイテッド | T-cell receptor binding to NY-ESO-1 and method of using same |
SG11202001319QA (en) | 2017-09-04 | 2020-03-30 | Agenus Inc | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
CN107881185A (en) * | 2017-11-21 | 2018-04-06 | 重庆天科雅生物科技有限公司 | A kind of single-stranded TCR carrier Ts and single-stranded TCR T cells production technology |
EP4298121A1 (en) | 2021-02-25 | 2024-01-03 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
WO2023047089A1 (en) | 2021-09-21 | 2023-03-30 | Oslo Universitetssykehus Hf | Binding proteins for terminal deoxynucleotidyl transferase (tdt) |
WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
WO1996018105A1 (en) * | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
AU728794B2 (en) * | 1996-03-05 | 2001-01-18 | Scripps Research Institute, The | Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens |
-
1998
- 1998-11-19 IL IL12714298A patent/IL127142A0/en unknown
-
1999
- 1999-11-18 WO PCT/IL1999/000622 patent/WO2000031239A1/en active Application Filing
- 1999-11-18 AU AU12927/00A patent/AU1292700A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000031239A1 (en) | 2000-06-02 |
AU1292700A (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL127142A0 (en) | Immune cells having predefined biological specificity | |
DE60026352D1 (en) | Biosensor | |
IL124903A0 (en) | An enzyme biosensor | |
EP1182450A4 (en) | Biosensor | |
IL129890A0 (en) | Modified bioreactor | |
GB9928968D0 (en) | Enzyme | |
GB9808145D0 (en) | Assay | |
EP1156105A4 (en) | Novel enzyme | |
GB9925161D0 (en) | Novel enzyme | |
GB9906245D0 (en) | Enzyme | |
GB9820532D0 (en) | Modified bioreactor | |
GB9818931D0 (en) | Photobioreactor | |
IL120445A0 (en) | Biosensor for cells | |
GB9803156D0 (en) | Assay | |
GB9821198D0 (en) | Enzyme | |
GB9809160D0 (en) | Assay | |
GB9820817D0 (en) | Enzyme | |
EP0986747A4 (en) | Improved biosensor | |
GB9924634D0 (en) | Enzyme | |
IL140295A0 (en) | Novel biocontrol agents | |
GB9908458D0 (en) | Enzyme | |
EP1012248A4 (en) | Novel thermophilic polymerase iii holoenzyme | |
GB9810997D0 (en) | Genes & enzymes | |
GB9823882D0 (en) | Enzyme | |
GB9826777D0 (en) | Enzyme |